DGX Stock Recent News
DGX LATEST HEADLINES
Quest Diagnostics Inc DGX reported on Tuesday that first-quarter 2025 sales of $2.65 billion, up 12.1% year over year, beat the consensus of $2.63 billion.
Quest Diagnostics Incorporated (NYSE:DGX ) Q1 2025 Results Conference Call April 22, 2025 8:30 AM ET Company Participants Shawn Bevec - Vice President of Investor Relations Jim Davis - Chairman, Chief Executive Officer, President Sam Samad - Chief Financial Officer Conference Call Participants Luke Sergott - Barclays Kevin Caliendo - UBS Patrick Donnelly - Citi Elizabeth Anderson - Evercore ISI Michael Cherny - Leerink Partners Pito Chickering - Deutsche Bank Noah Kava - Jefferies David Westenberg - Piper Sandler Michael Ryskin - Bank of America Andrew Brackmann - William Blair Jack Meehan - Nephron Research Erin Wright - Morgan Stanley Operator Welcome to the Quest Diagnostics First Quarter 2025 Conference Call. At the request of the company, this call is being recorded.
DGX delivers solid top-line growth in the first quarter of 2025.
Quest Diagnostics (DGX) came out with quarterly earnings of $2.21 per share, beating the Zacks Consensus Estimate of $2.15 per share. This compares to earnings of $2.04 per share a year ago.
Laboratory operator Quest Diagnostics beat Wall Street estimates for first-quarter profit on Tuesday, helped by robust demand for its diagnostic tests.
Quest Diagnostics Inc.'s stock fell 3.6% early Tuesday, after the company posted better-than-expected first-quarter earnings and backed its guidance, but said the early part of the quarter was slow.
First quarter revenues of $2.65 billion, up 12.1% from 2024 First quarter reported diluted earnings per share ("EPS") of $1.94, up 12.8% from 2024; and adjusted diluted EPS of $2.21, up 8.3% from 2024 Full year 2025 reported diluted EPS now expected to be between $8.62 and $8.87; and adjusted diluted EPS is expected to remain between $9.55 and $9.80 SECAUCUS, N.J. , April 22, 2025 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leading provider of diagnostic information services, today announced financial results for the first quarter ended March 31, 2025.
Quest Diagnostics (DGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DGX's first-quarter 2025 performance is likely to have been supported by the ongoing utilization of its Advanced Diagnostics and benefits from acquisitions.
Quest Diagnostics introduces AD-Detect Abeta, a new laboratory blood test, to detect Alzheimer's disease without any PET imaging and cerebral spinal fluid testing.